clinical trial · NCT04736173
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Non Small Cell Lung CancerNonsquamous Non Small Cell Lung CancerSquamous Non Small Cell Lung CancerLung CancerDomvanalimabZimberelimabCarboplatinPaclitaxelPemetrexedPembrolizumab
brief summary
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
started
Feb 8, 2021
primary completion
May 1, 2027
completion
May 1, 2027
last updated
May 1, 2026
official title
Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol